Sankalp Arora, MBBS, a second-year fellow at MD Anderson, presented data on FLT3 inhibitors in AML at the HemOnc Pulse Live. Dr. Rogers shares her career trajectory, what being a doctor is about, and a glimpse of her pet guinea pigs, Maple and Brady. Julie Braish, MBBCh, a third-year fellow at MD Anderson, presented data on azacitidine and venetoclax in HR-MDS and CMML. Experts discuss the link between dietary patterns and blood cancer risk and the shortcomings of epidemiological studies. Dr. Locke is a lead investigator of the ZUMA-1 and ZUMA-7 trials, which led to the FDA approval of axi-cel. The awards recognize early-, mid-, or senior-career experts who display excellence in the field. Co-Editor-in-Chief Mehdi Hamadani, MD, reflects on the importance of exchanging ideas and shaping the future of patient care. William Morice, MD, PhD, President and CEO of Mayo Clinic Laboratories, discussed a collaboration to expand cancer testing. Experts explore the impact of policy changes directed at the NIH to freeze research funds and terminate grants. Dr. Parekh’s laboratory focuses on developing personalized treatment strategies for patients with multiple myeloma. Douglas Graham, MD, PhD, a hematologist-oncologist specializing in pediatric leukemia, was recognized in Atlanta Magazine. Tycel Phillips, MD, discussed his presentation on BTK inhibitors from the International Ultmann Chicago Lymphoma Symposium. The award provides early-career researchers at NCCN Member Institutions with $150,000 in funding to support cancer research. Nirav Shah, MD, MSHP, recently presented at the International Ultmann Chicago Lymphoma Symposium on this subject. Joseph G. Jurcic, MD on the journey to survivorship for adults with either AML or ALL. Dr. Richard shares her passion for cellular therapy, how her mother’s leukemia diagnosis shaped her career, and more. Readmission rates were higher among patients with AML with high incomes compared with patients with low incomes. The award recognizes physician-scientists who made notable research achievements early in their first faculty appointment. The FDA approvals of CAR T-cell therapies have changed the treatment landscape for several hematologic malignancies. Dr. Gerds describes his journey to becoming a hematologist oncologist at the Cleveland Clinic.